Valuation Abbott Laboratories Börse Stuttgart
Stocks
ABL
US0028241000
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.73 EUR | -0.21% |
|
+6.76% | -16.69% |
| 07-17 | Abbott investigates two separate cyber incidents, says no operations affected | RE |
| 07-17 | Abbott Laboratories Seen on Track for H2 Growth Acceleration, RBC Says | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 177,073 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -18.72% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 200,454 | 192,817 | 189,013 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -9.81% | -3.81% | -1.97% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 28.4x | 22.1x | 19.2x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 4.38x | 3.44x | 3.21x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -7.76x | 0.8x | 1.3x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.52x | 3.24x | 3.02x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.98x | 3.53x | 3.22x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.5x | 13.4x | 12x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 17.1x | 14.8x | 13.2x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 25.3x | 20.6x | 18.5x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.96% | 4.85% | 5.4% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.587 | 2.721 | 2.858 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.54% | 2.68% | 2.81% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.584 | 4.603 | 5.284 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 72.2% | 59.1% | 54.1% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,312 | 54,699 | 58,667 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,939 | 14,441 | 15,804 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,716 | 13,031 | 14,322 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,441 | 8,073 | 9,095 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,381 | 15,744 | 11,941 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 101.66 | 101.66 | 101.66 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,741,813 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 18.9x | 3.31x | 11.63x | 3.57% | 107B | ||
| 16.91x | 0.19x | 11.95x | 0.78% | 59.14B | ||
| 31.81x | 7.73x | 20.21x | 1.26% | 51.89B | ||
| 38.49x | 3.07x | 10.49x | 2.49% | 42.57B | ||
| 37.27x | 1.36x | 12x | 0.26% | 32.88B | ||
| 30.92x | 5.51x | 17.57x | -.--% | 29.21B | ||
| 41.86x | 7.32x | 26.41x | 0.25% | 24.89B | ||
| 23.62x | 3.45x | 12.41x | 1.23% | 20.9B | ||
| 45.81x | 6.18x | 19.84x | 0.47% | 20B | ||
| Average | 31.73x | 4.24x | 15.83x | 1.15% | 43.12B | |
| Weighted average by Cap. | 28.05x | 3.81x | 14.59x | 1.67% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABL Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
















